Characterization of NKT-cell hybridomas expressing invariant T-cell antigen receptors. 2007

Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
Division of Immunobiology, Research Section of Pathophysiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.

Two natural killer T (NKT)-cell hybridomas were established by fusing sorted NKT cells with BW1100 thymoma cells. The first hybridoma line, 1B6, was CD4(+)8(-), whereas the second one, 2E10, was CD4(low)8(-). Initial characterizations revealed that both cell lines expressed an invariant T cell antigen receptor, which could be readily detected with alpha-galactosylceramide-loaded CD1d : Ig fusion protein (alpha-GalCer/CD1d). Sequence analyses of the alpha and beta chains of the T cell receptor V genes revealed that 1B6 and 2E10 cells expressed V alpha 14J alpha 18/V beta 8.2D beta 2J beta 2.7 and V alpha 14J alpha 18/V beta 8.1D beta 1J beta 1.1, respectively. When these hybridoma cells were stimulated with immobilized anti-CD3 monoclonal antibodies, alpha-GalCer/CD1d, or alpha-GalCer in the presence of antigen-presenting cells, they produced IL-4 and IFN-gamma. The expression levels of CD69, CD154, and CD178 were concomitantly up-regulated on both hybridomas upon stimulation. Because it is difficult to isolate a sufficient number of NKT cells, these hybridomas should provide useful platforms to study a variety of functions of NKT cells.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000945 Antigens, Differentiation, T-Lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function. Antigens, Differentiation, T-Cell,Differentiation Antigens, T-Cell,L3T4 Antigens,Leu Antigens, T-Lymphocyte,T-Cell Differentiation Antigens,T-Lymphocyte Differentiation Antigens,T6 Antigens,Antigens, Differentiation, T Lymphocyte,Differentiation Antigens, T Lymphocyte,Antigens, L3T4,Antigens, T-Cell Differentiation,Antigens, T-Lymphocyte Differentiation,Antigens, T-Lymphocyte Leu,Antigens, T6,Differentiation Antigens, T Cell,Differentiation Antigens, T-Lymphocyte,Leu Antigens, T Lymphocyte,T Cell Differentiation Antigens,T Lymphocyte Differentiation Antigens,T-Lymphocyte Leu Antigens
D013945 Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed) Carcinoma, Thymic,Carcinomas, Thymic,Thymic Carcinoma,Thymic Carcinomas,Thymomas
D013953 Thymus Neoplasms Tumors or cancer of the THYMUS GLAND. Cancer of Thymus,Thymus Cancer,Thymus Tumors,Cancer of the Thymus,Neoplasms, Thymic,Neoplasms, Thymus,Thymic Cancer,Thymic Neoplasms,Thymic Tumors,Cancer, Thymic,Cancer, Thymus,Cancers, Thymic,Cancers, Thymus,Neoplasm, Thymic,Neoplasm, Thymus,Thymic Cancers,Thymic Neoplasm,Thymic Tumor,Thymus Cancers,Thymus Neoplasm,Thymus Tumor,Tumor, Thymic,Tumor, Thymus,Tumors, Thymic,Tumors, Thymus
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2

Related Publications

Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
January 1988, Archivum immunologiae et therapiae experimentalis,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
July 2007, Nature,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
September 1989, Journal of immunology (Baltimore, Md. : 1950),
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
April 2010, Seminars in immunology,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
January 2018, Frontiers in immunology,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
February 2009, Immunology and cell biology,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
December 1989, Journal of immunology (Baltimore, Md. : 1950),
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
April 1988, Hybridoma,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
April 2016, Journal of autoimmunity,
Dashtsoodol Nyambayar, and Kazuya Iwabuchi, and Emma Hedlund, and Satoko Murakawa, and Keiko Shirai, and Chikako Iwabuchi, and Yujiroh Kon, and Yusei Miyazaki, and Yoshiki Yanagawa, and Kazunori Onoé
May 1983, The Journal of experimental medicine,
Copied contents to your clipboard!